TIDMERGO

RNS Number : 9974X

Ergomed plc

10 May 2021

PRESS RELEASE

Mark Enyedy Appointed to Board as Non-Executive Director

Guildford, UK - 10 May 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that Mark Enyedy will join the Board as a Non-Executive Director with effect from 10 June 2021.

Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.

Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.

Mr Enyedy also serves on the Boards of Directors of The American Cancer Society of Eastern New England and LogicBio Therapeutics, Inc. (Nasdaq: LOGC). He holds a J.D. from Harvard Law School and a B.S. from Northeastern University.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Mark has extensive corporate development experience in the US, UK and globally from his time in senior public company strategic leadership roles. Throughout his career he has achieved an outstanding and consistent track record of building new businesses through organic growth, corporate development, and M&A. Over the past 20 years, he has been strongly focused on rare disease and oncology, and brings to Ergomed exceptional levels of expertise, insight and connections which will support our continuing drive to strengthen our global leadership in these sectors. Mark is an outstanding addition to Ergomed, and on behalf of the Board, I am delighted to warmly welcome him to his new position."

Mark Enyedy said: "Ergomed is at an exciting stage in its development. The Company's success in recent years reflects the continued strong execution of both its organic and inorganic growth strategy, creating leadership positions in its chosen high-growth specialist markets. I look forward to working closely with the management team to develop innovative strategies that will accelerate the company's continued international growth."

Mr Mark Joseph Enyedy, aged 57, holds or has held directorships in the five years preceding his appointment at Ergomed as follows:

 
 Current Directorships:           Akebia Therapeutics Inc 
                                   Immunogen BioPharma (Ireland) Limited 
                                   Immunogen Europe Limited 
                                   Immunogen Inc 
                                   Immunogen Securities Corp 
                                   LogicBio Therapeutics Inc 
                                   The American Cancer Society of 
                                   Eastern New England 
                                   The Biotechnology Innovation Organization 
 Directorships in the past five   Fate Therapeutics Inc 
  years:                           Immunogen (Bermuda) Ltd 
                                   Keryx Biopharmaceuticals, Inc. 
                                 ------------------------------------------- 
 

ENDS

Enquiries:

 
 Ergomed plc                                        Tel: +44 (0) 1483 402 
                                                                      975 
 Miroslav Reljanović (Executive 
  Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                            Tel: +44 (0) 20 7260 
                                                                     1000 
 Freddie Barnfield / Matthew O'Dowd 
  (Nominated Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications                  Tel: +44 (0) 20 3709 
  - for UK enquiries                                                 5700 
 Chris Gardner / Matthew Neal                 ergomed@consilium-comms.com 
 Angela Gray / Olivia Manser 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFSSESIAIIL

(END) Dow Jones Newswires

May 10, 2021 02:00 ET (06:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2022 a May 2022 Haga Click aquí para más Gráficas Ergomed.
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De May 2021 a May 2022 Haga Click aquí para más Gráficas Ergomed.